

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> application of:	Art Unit: 1632
BORUNDA, J. et al.	Examiner: CHEN, S. L.
Appl. No. 10/724,292	Atty. Docket: 061537-0036US
Filed: 1 December 2003	Confirmation No.: 4513
For: Recombinant Adenoviral Vectors And Their Utility In The Treatment Of Various Types Of Fibrosis: Hepatic, Renal, Pulmonary, As Well As Hypertrophic Scars	Customer No.: 09629

**RESPONSE TO FINAL OFFICE ACTION**

**MAIL STOP AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This communication is being submitted in response to the Non-Final Office Action of  
15 January 2009.

Applicants do not believe that any extensions of time are necessary to maintain the pendency of this application beyond what may be submitted herewith. If, however, any additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a), and any fees required, including fees for net addition of claims, are hereby authorized to be charged to Deposit Account No. 50-0310.

**Amendments to the claims** begin on page 2.

**Remarks** begin on page 3.